SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--FibroGen, Inc. today announced data from research on the company’s proprietary hypoxia-inducible factor (HIF) prolyl hydroxylase inhibitors (PHI), which are a novel class of small molecules being evaluated and developed for multiple therapeutic applications. The data were reported at the Keystone Conference “Molecular, Cellular, Physiological, and Pathogenic Responses to Hypoxia” held in Vancouver, British Columbia, January 15–20, 2008.
